NCT05576415View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions
Dry Eye Disease
Interventions
DRUG

Varenicline Tartrate Nasal Spray

Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.

Trial Locations (1)

Unknown

Huashan Hospital, Shanghai

Sponsors

Collaborators (1)

Oyster Point Pharma, Inc.
All Listed Sponsors
collaborator

Oyster Point Pharma, Inc.

INDUSTRY

lead

Corxel Pharmaceuticals

INDUSTRY

NCT05576415 - Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease | Biotech Hunter | Biotech Hunter